Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.

abstract：:A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...

journal_title：Leukemia & lymphoma

authors： Quitt M,Bazac I,Gross B,Aghai E

更新日期：1994-11-01 00:00:00

abstract：:Primary central nervous system (PCNS) lymphoma is a relatively rare disease. The Epstein-Barr virus (EBV) has often been implicated in the development of lymphomas. Few cytogenetic. studies on PCNS lymphomas have been reported. We describe here an unusual case of PCNS B cell lymphoma, centroblastic polymorphic type wi...

journal_title：Leukemia & lymphoma

authors： Zattara-Cannoni H,Horshowski N,Figarella-Branger D,Dufour H,Grisoli F,Vagner-Capodano AM

更新日期：1996-05-01 00:00:00

abstract：:Tumor necrosis factor alpha (TNF-alpha) and lymphotoxin alpha (LT-alpha) have been shown to play an important role in the pathogenesis of limphoproliferative disease. Both cytokines regulate cell-survival and cell-death in leukemic cells. TNF-alpha and LT-alpha are highly produced in chronic lymphotic leukemia (CLL) a...

journal_title：Leukemia & lymphoma

authors： Jevtovic-Stoimenov T,Kocic G,Pavlovic D,Macukanovic-Golubovic L,Marjanovic G,Djordjevic V,Tosić N,Pavlović S

更新日期：2008-11-01 00:00:00

abstract：:Central nervous system (CNS) relapse is a challenging complication in patients with diffuse large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom prophylactic treatment may play a significant role, is critical. We calculated the incidence of CNS relapse and evaluated the risk factors...

journal_title：Leukemia & lymphoma

authors： Chihara D,Oki Y,Matsuo K,Onoda H,Taji H,Yamamoto K,Morishima Y

更新日期：2011-12-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-ce...

journal_title：Leukemia & lymphoma

authors： Bhat SA,Woyach JA

更新日期：2020-03-01 00:00:00

abstract：:Recombinant interferon alpha-2b (IFN-alpha2) has direct and indirect antiproliferative effects in lymphoma, and may augment cytotoxicity when combined with chemotherapy. CALGB 8691 is a randomized study of daily oral cyclophosphamide (CPA) at 100 mg/m2 with or without IFN-alpha2 at 2 x 106 IU/m2 three times per week, ...

journal_title：Leukemia & lymphoma

authors： Smith SM,Johnson J,Cheson BD,Canellos G,Petroni G,Oken M,Duggan D,Hurd D,Gockerman JP,Parker B,Prchal J,Peterson BA,Cancer and Leukemia Group B.,Eastern Cooperative Oncology Group.

更新日期：2009-10-01 00:00:00

abstract：:Denaturing high-performance liquid chromatography (dHPLC) was developed to screen DNA variations by separating heteroduplex and homoduplex DNA fragments by ion-pair reverse-phase liquid chromatography. In this study, we have evaluated the dHPLC screening method and direct sequencing for the detection of GATA1 mutation...

journal_title：Leukemia & lymphoma

authors： Amorim MR,Figueiredo AB,Splendore A,Magalhães IQ,Pombo-de-Oliveira MS,El-Jaick KB,D'andrea ML,Aquino J,Alencar DM,Brandalise SR,Burlemaqui L,Cardoso TC,Carvalho EG,Coser VM,Costa I,Dorea D,Drumond M,Lopes VG,Mendonça

更新日期：2009-05-01 00:00:00

abstract：:Thymosin β4 (Tβ4) was originally isolated as a thymic hormone from calf thymosin fraction 5 which exhibited both immune and endocrine functions in vivo and in vitro. Tβ4 is a ubiquitous peptide located in various tissues of mammalian species and other vertebrate classes. Recent studies on the molecular cloning and seq...

journal_title：Leukemia & lymphoma

authors： Kudo J,Shimamura R,Ishibashi H,Niho Y

更新日期：1991-01-01 00:00:00

abstract：:Richter's transformation (RT) refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Approximately, 2-10% of patients with CLL develop RT, most often as diffuse large B-cell lymphoma. To assess the incidence of RT, we examined risk factors for RT and death among patien...

journal_title：Leukemia & lymphoma

authors： Ben-Dali Y,Hleuhel MH,da Cunha-Bang C,Brieghel C,Poulsen CB,Clasen-Linde E,Bentzen HHN,Frederiksen H,Christiansen I,Nielsen LH,Enggaard L,Helleberg M,Clausen M,Frederiksen M,Pedersen RS,Niemann CU,Andersen MA

更新日期：2020-06-01 00:00:00

abstract：:HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

journal_title：Leukemia & lymphoma

authors： Burke LP,Kukoly CA

更新日期：2008-02-01 00:00:00

abstract：:We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

journal_title：Leukemia & lymphoma

authors： Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

更新日期：2016-09-01 00:00:00

abstract：:Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

journal_title：Leukemia & lymphoma

authors： Bhatt VR,Gundabolu K,Koll T,Maness LJ

更新日期：2018-01-01 00:00:00

abstract：:The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present obs...

journal_title：Leukemia & lymphoma

authors： Millot F,Brizard F,Sorel N,Preudhomme C,Cividin M,Guilhot F,Brizard A

更新日期：2005-06-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:The aims of this study were: 1) to identify the type of bcl-2 rearrangement in a Brazilian group of FL patients and 2) to correlate it to clinical features, International Prognostic Index (IPI), histological subtype, response to treatment and clinical outcome. We reviewed the diagnosis of 48 patients with FL and inves...

journal_title：Leukemia & lymphoma

authors： Colleoni GW,Duarte LC,Kerbauy FR,Noguti MA,Da Silva ID,Otsuka AY,Alves AC,Silva MR

更新日期：2004-02-01 00:00:00

abstract：:Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

journal_title：Leukemia & lymphoma

authors： Sever M,Newberry KJ,Verstovsek S

更新日期：2014-12-01 00:00:00

abstract：:Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six ...

journal_title：Leukemia & lymphoma

authors： Gupta S,Bagel B,Gujral S,Subramanian PG,Khattry N,Menon H,Nair R

更新日期：2012-11-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

journal_title：Leukemia & lymphoma

authors： Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

更新日期：2013-05-01 00:00:00

abstract：:The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

journal_title：Leukemia & lymphoma

authors： James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

更新日期：1998-01-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:Human mantle cell lymphoma (MCL) cell lines are scarce and have been only sporadically described and validated, and only a few have been thoroughly molecularly or genetically characterized. We describe here the successful establishment of a new MCL line, PF-1, with typical MCL characteristics. Culturing primary MCL ce...

journal_title：Leukemia & lymphoma

authors： Pham LV,Vang MT,Tamayo AT,Lu G,Challagundla P,Jorgensen JL,Rollo AA,Ou Z,Zhang L,Wang M,Ford RJ

更新日期：2015-01-01 00:00:00

abstract：:Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene repertoire in 14 patients who received Rituximab post allo-HCT and expl...

journal_title：Leukemia & lymphoma

authors： Papalexandri A,Karypidou M,Stalika E,Kotta K,Touloumenidou T,Zerva P,Paleta A,Mallouri D,Batsis I,Sakellari I,Kotsianidis I,Anagnostopoulos A,Hadzidimitriou A,Margaritis D,Stamatopoulos K

更新日期：2019-07-01 00:00:00

abstract：:Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

journal_title：Leukemia & lymphoma

authors： Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

更新日期：1993-02-01 00:00:00

abstract：:Aim of this multicenter-study was to evaluate rate and duration of remissions and to examine toxicity of cladribine in low-grade lymphomas as first-line therapy or in first relapse using intermittent 2-hour-infusion of cladribine. A total of 294 courses, median of 5 courses per patient, were administered to 66 evaluab...

journal_title：Leukemia & lymphoma

authors： Rummel MJ,Chow KU,Jäger E,Leimer L,Hossfeld DK,Bergmann L,Peters HD,Hansmann ML,Meyer A,Hoelzer D,Mitrou PS

更新日期：1999-09-01 00:00:00

abstract：:BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

journal_title：Leukemia & lymphoma

authors： Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

更新日期：2013-06-01 00:00:00

abstract：:Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

journal_title：Leukemia & lymphoma

authors： Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

更新日期：1998-08-01 00:00:00

abstract：:Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificit...

journal_title：Leukemia & lymphoma

authors： Hantschel O,Rix U,Superti-Furga G

更新日期：2008-04-01 00:00:00

abstract：:Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

journal_title：Leukemia & lymphoma

authors： Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

更新日期：1995-01-01 00:00:00

abstract：:During the last few years it has been shown that intensive or continuing chemotherapy of patients with advanced chronic lymphocytic leukemia prolongs survival. In the search for new effective drugs with tolerable toxicity, mitoxantrone was evaluated in this phase 2 study. Seven of 11 previously untreated patients achi...

journal_title：Leukemia & lymphoma

authors： Hansen MM,Hansen SW,Pedersen-Bjergaard J,Nissen NI

更新日期：1992-07-01 00:00:00